Metanoia Press · In preparation · Synthetic
Metanoia's focus is the natural psychedelics, but the family cannot be understood without LSD. It was the molecule that opened the modern era, shaped a culture, was banned, and — in 2026 — returned to serious clinical research with some of the strongest data the field has produced. Our forthcoming book tells that full arc: the accidental discovery, the science, the fall, and the remarkable comeback.
What the Book Will Cover
Albert Hofmann, ergot, and the accidental first dose — how a Swiss chemistry program produced the most famous psychedelic on earth.
Extraordinary potency at microgram doses, a long duration, and its grip on the 5-HT2A receptor — plus why it lasts so long.
Early psychiatric promise, cultural explosion, and Schedule I — the decades the science went dark.
Pharmaceutical LSD back in Phase 3 trials — for depression and for anxiety — with striking results.
LSD was first synthesized by Albert Hofmann in 1938 and its effects discovered in 1943. It is astonishingly potent — active at millionths of a gram — and works, like the natural tryptamines, primarily through the 5-HT2A serotonin receptor, with an unusually long grip that helps explain its many-hour duration. After decades in prohibition, its clinical chapter reopened dramatically: in 2026, pharmaceutical LSD formulations advanced through late-stage trials, with one program reporting one of the largest antidepressant effect sizes on record and another receiving breakthrough designation for generalized anxiety.
Reliability: pharmacology and history are well established (strong); the 2026 clinical results are late-stage but await full peer-reviewed publication and independent replication. Full sources will accompany the finished book.